fluorobenzenes has been researched along with Hepatopulmonary Syndrome in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chang, CC; Chuang, CL; Hsieh, HG; Huang, HC; Lee, FY; Lee, SD; Lee, WS; Lin, HC; Wang, SS | 1 |
1 other study(ies) available for fluorobenzenes and Hepatopulmonary Syndrome
Article | Year |
---|---|
Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
Topics: Administration, Oral; Animals; Disease Models, Animal; Down-Regulation; Fluorobenzenes; Hemodynamics; Hepatopulmonary Syndrome; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lung; Male; Neovascularization, Pathologic; Pyrimidines; Rats; Rats, Sprague-Dawley; Reference Values; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |